AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02877940 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ProSeal Laryngeal mask airway
Description: ProSeal was inserted in mechanically ventilated patients undergoing elective surgeries.
Study NCT02877940 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal Tube Suction- Disposable
Description: LTS-D was inserted in mechanically ventilated patients undergoing elective surgeries.
Study NCT02877940 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: i-gel
Description: i-gel was inserted in mechanically ventilated patients undergoing elective surgeries.
Study NCT03753009 — intervention group
Intervention type: PROCEDURE
Intervention: corneal cross-linking
Description: Epithelium-off CXL was performed according to the Siena (Dresden modified) protocol: 2% pilocarpine was instilled 30 minutes before treatment, the epithelium was removed using a blunt knife. An isotonic solution of riboflavin 0.1% and dextran 20% was instilled for 10 minutes of corneal soaking before starting UV-A irradiation. The solution was administered every 3 minutes for a total of 30 minutes of UV-A exposure at 3mW/cm2.~The iontophoresis device was filled with a hypoosmolar riboflavin 0.1% dextran-free solution enriched with ethylenediaminetetraacetic acid and trometamol. The device was then connected to a constant current generator initially set at 0.5 mA and increased to 1.0 mA to find out the individual tolerance. Iontophoresis was then performed for 5 minutes. The corneal device was then removed before performing UVA irradiation. During the irradiation phase (10 mW/cm2 for 9 minutes), good fluorescence was clearly detectable. The total treatment time was 14 minutes.
Study NCT00570817 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 12 hours of prehydration
Description: 12 hours of prehydration with an infusion rate of 150 ml/m2/hour with a solution of 5% glucose with 40 mmol sodium bicarbonate/L and 20 mmol potassium chloride/L.
Study NCT01990092 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metanx
Description: Metanx is a prescription medical food.
Study NCT01990092 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02936934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Interventions pre-specified to be administered to participants:~Abdominal hysterectomy Block Anesthesia: bupivacaine 0.5% + 25 micrograms of fentanyl 10mg / kg metamizol sodium intravenously during surgery~Intravenous infusion:~200μg / kg of morphine + 3g metamizole sodium + 3mg / kg 2% lidocaine + 500mL saline solution. Time administration:24hours
Study NCT02936934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Interventions pre-specified to be administered to participants:~Abdominal hysterectomy Block Anesthesia: bupivacaine 0.5% + 25 micrograms of fentanyl 10mg / kg metamizol sodium intravenously during surgery~Intravenous infusion:~150μg / kg of oxycodone + 3g metamizole sodium + 3mg / kg 2% lidocaine + 500mL saline solution. Time administration: 24hours.
Study NCT01768988 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Conventional treatment + placebo (during 90 days).~Conventional treatment comprises a WHO step ladder approach and comprises in most cases:~1. Paracetamol 1g/8h~2. Weak opioid (tramadol at maximal doses of 400 mg/24h)~3. Strong opioid in substitution of weak opioid if not efficient (e. g. morphine, oxycodone, fentanyl patch, hidromorphone), at the needed doses to control pain (VAS \< 3).
Study NCT01768988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Treatment during 90 days with conventional treatment + pregabalin.~Pregabalin doses were reached until the maximal doses (300 mg/12h) depending on patient tolerability. An escalating dose scheme were desigened as follows, to avoid tolerability problems:~Week 1 75-0-75 Week 2 75-0-150 Week 3 150-0-150 Week 4 150-0-300 Week 5 300-0-300 (until the end of study)~Conventional treatment comprises a WHO step ladder approach and comprises in most cases:~1. Paracetamol 1g/8h~2. Weak opioid (tramadol at maximal doses of 400 mg/24h)~3. Strong opioid in substitution of weak opioid if not efficient (e. g. morphine, oxycodone, fentanyl patch, hidromorphone), at the needed doses to control pain (VAS \< 3).
Study NCT00611338 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV Skills-based Prevention
Study NCT01456689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGH447
Study NCT01456689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Study NCT02017379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythromycin
Study NCT02017379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopromide
Study NCT00844207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed combination of Azithromycin and Chloroquine
Description: Pfizer will provide the study medications, fixed combination azithromycin/chloroquine tablets (250 mg/155 mg, base), The study treatment is single dose.
Study NCT00844207 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin and Chloroquine
Description: Pfizer will provide Zithromax (500 mg) and Aralen (500 mg containing 300 mg chloroquine base). The study treatment is single dose.
Study NCT03985345 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intravaginal device (probe) EMY
Description: Free use of EMY and its mobile application for 10 minutes during 5 different days per week.
Study NCT01237340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saizen®
Description: Single dose of Saizen® (recombinant human growth hormone, r-hGH) solution for injection will be administered subcutaneously for 26 weeks. Dosage regimen will be in accordance with marketed formulation of Saizen® (freeze-dried formulation), based on locally approved product labeling.
Study NCT01910116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Shinbaro
Description: GCSB-5 (Shinbaro) is a mixture of six purified oriental herb extracts in a fixed ratio, namely, Saposhnikovia divaricata Schischk, Glycine max Merrill, Cibotium barometz J. Smith, Eucommia ulmoides Oliver, Achyranthes japonica Nakai, and Acanthopanax sessiliflorus Seem
Study NCT01910116 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The study medication and placebo were identical in appearance.
Study NCT05330403 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Moxibustion
Description: In this study, suspended moxibustion was performed by holding an ignited moxa stick at a certain distance (about 3-4 cm) over the skin surface, keeping the moxibustion Site warm without burning the skin.~In the heart meridian intervention group, moxibustion was applied over Site 4 (HT3) of the heart meridian.~In the lung meridian intervention group, moxibustion was performed over Site 1 (LU5) of the lung meridian.
Study NCT02742467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perindopril plus Amlodipine
Description: Group 1
Study NCT02742467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perindopril plus Hydrochlorothiazide
Description: Group 2
Study NCT02742467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perindopril plus Hydrochlorothiazide
Description: Group 2
Study NCT02742467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine plus Hydrochlorothiazide
Description: Group 3
Study NCT02742467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine plus Hydrochlorothiazide
Description: Group 3
Study NCT02024451 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radial shock wave
Description: radial shock wave: Treatment point is the origin attachment of upper trapezius at the external occipital protuberance. Radial shock wave therapy will be performed once per week, and will be continued for 3 weeks. Acetaminophen will be prescribed as rescue medication, and the amount given will be recorded at the end of the study.
Study NCT02024451 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture is performed at Fenfchi (GB20) point over upper back by the same physiatrist to all patients.
Study NCT01591317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Tablets orally
Study NCT02289352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine
Study NCT02289352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine
Study NCT02289352 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00685685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg tablets
Description: 40 mg tablet administered after an overnight fast of at least 10 hours
Study NCT00685685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovastatin (Mevacor®) 40 mg Tablets
Description: 40 mg tablet administered after an overnight fast of at least 10 hours
Study NCT01958190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus and Sirolimus
Description: Arm 1 once daily combination therapy of normal dosed extended-release tacrolimus and prednisone for 3 months and monotherapy once daily extended-release tacrolimus thereafter up to 3 years after liver transplantation.~Arm 2 once daily combination therapy of low doses sirolimus and extended-release tacrolimus and prednisone for 3 months and combination therapy of low dose sirolimus and extended-release tacrolimus thereafter for up to 3 years after liver transplantation Continue Advagraf (5-10 ng/ml) and 7.5 mg prednison; lower or discontinue steroids after day 180 at the discretion of the treating physician Conversion to sirolimus (3-5 ng/ml) and decrease Advagraf (3-5 ng/ml); 7.5 mg prednisone and lower or discontinue steroids after day 180 at the discretion of the treating physician
Study NCT01958190 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Patient received standard-dose of Tracrolimus Advagraf (5-10 ng/ml) and 7.5 mg prednison; lower or discontinue steroids after day 180 at the discretion of the treating physician
Study NCT03931967 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MR-proADM
Description: to evaluate the plasmatic level of MR-proADM and endothelin-1 in the first five days of ICU stay.
Study NCT01221727 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Denosumab
Description: Eighteen (18) subjects will receive 1 fixed dose administration of denosumab.
Study NCT01221727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: All subjects will receive two oral dose administrations of midazolam.
Study NCT03525535 — intervention group
Intervention type: OTHER
Intervention: data collection
Description: data from patient included will be collected during the study
Study NCT01845454 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: trūFreeze™ Spray Cryotherapy
Description: The trūFreeze™ System consists of a console containing a holding tank for medical grade liquid nitrogen and a spray tip CSATM Catheter. The physician uses the console to initiate and control the flow and duration of the cryogen spray. The liquid nitrogen is propelled through a spray CSATM Catheter to the selected site by pressure in the holding tank and freezing techniques are monitored by direct visualization with an endoscope. Once the freezing is completed, the cryogen flow is terminated and the thawing system may be engaged to allow accessory removal. If multiple cycles are used, thawing is initiated at the end of the procedure.
Study NCT04026061 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FMA group
Description: A person-centred, tailored tablet intervention, called FindMyApps (FMA). The intervention consists of the FMA training to use the tablet and the FMA selection tool to help users find apps for self-management and meaningful activities that fit their needs, wishes and abilities
Study NCT04026061 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Receiving an introductory tablet training and some links to websites that recommend usable apps for people with dementia in general
Study NCT03519464 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Gardasil 9
Description: Gardasil 9 administered as a 0.5ml intramuscular injection in the deltoid region of the upper arm or in the anterolateral area of the thigh, 3-dose regimen of injections given at month 0, month 2, and month 6.
Study NCT02046577 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo liquid
Study NCT01472289 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous Bone Marrow Mononuclear cells (BMMNCs)
Description: Multiple intramuscular injections of concentrated bone marrow derived mononuclear cells (0.5 cc/injection) into the ischemic muscle of the affected limb.
Study NCT00598910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omacor
Description: n-3 PUFA
Study NCT00598910 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03029871 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad5-yCD/mutTKSR39rep-ADP Adenovirus
Description: oncolytic adenovirus
Study NCT02830763 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CNT-02
Description: Each subject will take 2.0g of the investigational product orally 3 times a day after every meal. Unless an apparent worsening of symptoms or unacceptable adverse event occurs, the subject will continue to take the investigational product for up to 6 months.
Study NCT02538003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCB01-0371 Tablet 800 mg(R)
Description: Reference: taken drug before meal
Study NCT02538003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCB01-0371 Tablet 800 mg(T)
Description: Test: taken drug after meal
Study NCT00911625 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5 units/kg daily insulin
Description: Participants randomized to receive this intervention will receive a standard-dose of 0.5 units/kg daily insulin. Half of this dose will be given as glargine and the other half will be given as glulisine.
Study NCT00911625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25 units/kg daily insulin
Description: Participants randomized to receive this intervention will receive an experimental dose of 0.25 units/kg daily insulin. Half of this dose will be given as glargine and the other half will be given as glulisine.
Study NCT04280536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort A
Description: Oral FTD/TPI at RP2D will be administered until disease progression, intolerable toxicity or patient withdrawal.
Study NCT04280536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort B
Description: Oral FTD/TPI at RP2D will be administered until disease progression, intolerable toxicity or patient withdrawal.
Study NCT02809742 — intervention group
Intervention type: DRUG
Intervention: Ropivacaine
Description: Epidural : automatic intermittent boluses associated with patient controlled bolus using ropivacaine
Study NCT00771004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone 30 mg, tablets, orally, once daily for one week; increased to Pioglitazone 45 mg, tablets, orally, once daily for up to two weeks.
Study NCT00771004 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pioglitazone placebo-matching tablets, orally, once daily for up to three weeks.
Study NCT02183155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam - low
Study NCT02183155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam - medium
Study NCT02183155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam - high
Study NCT02183155 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02183155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Extended-release indomethacin
Study NCT00738413 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferoxamine
Description: Deferoxamine will be administered subcutaneously over 8 hours for 6 days at a dose of 40 mg/kg.
Study NCT00738413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferoxamine
Description: Deferoxamine will be administered subcutaneously over 8 hours for 6 days at a dose of 40 mg/kg.
Study NCT00738413 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferasirox
Description: Deferasirox will be orally administered at a dose of 30 mg/kg once daily for 6 days.
Study NCT00738413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Description: Deferasirox will be orally administered at a dose of 30 mg/kg once daily for 6 days.
Study NCT02231463 — intervention group
Intervention type: OTHER
Intervention: neutral positioning, PEEP 0 cm H2O
Description: neutral positioning, PEEP 0 cm H2O
Study NCT02231463 — intervention group
Intervention type: OTHER
Intervention: neutral positioning, PEEP 5cm H2O
Description: neutral positioning, PEEP 5cm H2O
Study NCT02231463 — intervention group
Intervention type: OTHER
Intervention: neutral positioning, PEEP 10cm H2O
Description: neutral positioning, PEEP 10cm H2O
Study NCT02231463 — intervention group
Intervention type: OTHER
Intervention: Trendelenburg positioning -20°, PEEP 0 cmH2O
Description: Trendelenburg positioning -20°, PEEP 0 cmH2O
Study NCT02231463 — intervention group
Intervention type: OTHER
Intervention: Trendelenburg positioning -20°, PEEP 5 cmH2O
Description: Trendelenburg positioning -20°, PEEP 5 cmH2O
Study NCT02231463 — intervention group
Intervention type: OTHER
Intervention: Trendelenburg positioning -20°, PEEP 10 cmH2O
Description: Trendelenburg positioning -20°, PEEP 10 cmH2O
Study NCT04341168 — intervention group
Intervention type: OTHER
Intervention: this study is non- interventional
Description: this study is non- interventional
Study NCT02907710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Description: intravenous infusion
Study NCT02907710 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DDP
Study NCT02907710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DDP
Study NCT00773136 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bimatoprost Suspension
Description: see prior
Study NCT03612011 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Onco-Repair/ Placebo
Description: Cream must be applied twice a day, in the morning and evening, on the hands and feet (palmo-plantar areas and interdigital spaces included) previously cleaned with Atoderm Intensive Foaming Gel, chosen as a standardized hygiene product.
Study NCT03612011 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Onco-Repair/ Placebo
Description: Cream must be applied twice a day, in the morning and evening, on the hands and feet (palmo-plantar areas and interdigital spaces included) previously cleaned with Atoderm Intensive Foaming Gel, chosen as a standardized hygiene product.
Study NCT00941668 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triclosan/Copolymer/fluoride toothpaste
Description: Twice daily usage
Study NCT00941668 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sodium monofluorophosphate toothpaste
Description: Twice daily usage
Study NCT01866397 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cidofovir pharmacokinetics
Description: Blood samples were drawn before and 15, 30, 60, 120, 240, 360, 720 and 1440 minutes after the start of the cidofovir infusion. Plasma and ultrafiltration samples were collected from the outlet of the ultrafiltrate compartment of the hemofilter.
Study NCT05104021 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: game
Description: The game is played with a maximum of four people. Beginning points are marked with blue, red, yellow and green colors, the game progress direction is The starting color for the player is determined with the help of arrows. Dice with the biggest number The child who throws starts the game first from the starting point that belongs to him. Play ground Each child who completes a circuit around him reads from his second point. it tries to go inwards (to the world square) in the direction it points. Equivalent to card check box The next child draws one of the face down cards. the instruction written on the back of the card.~implements. Then he puts the card on the back of the other cards. Cards are reward (go forward), penalty (backward) git) cards. Coming second to the same frame during the game The child first starts the game from the starting point of the child in the square. First The child who manages to enter the world square wins the game.
Study NCT03498898 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chronic use of Beta adrenergic receptor blocker
Description: Chronic use of Beta adrenergic receptor blocker
Study NCT00408395 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Description: Seasonal Influenza Vaccine
Study NCT01127945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: statin
Description: 1. adding atorvastatin 80mg, po on day (1 to 3) acute heart failure therapy~2. acute heart failure therapy
Study NCT01127945 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: statin
Description: 1. adding atorvastatin 80mg, po on day (1 to 3) acute heart failure therapy~2. acute heart failure therapy
Study NCT00660270 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pancreatic Surgery
Study NCT00660270 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Study NCT00660270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin